Urologists typically prescribe three main classes of medication to prevent kidney stones from coming back: thiazide diuretics to reduce calcium in the urine, potassium citrate to inhibit stone crystallization, and allopurinol to lower uric acid levels. The specific drug a patient receives depends on the type of stone they form and what a 24-hour urine test reveals about their body chemistry. For example, a patient who keeps forming calcium oxalate stones with low urinary citrate would likely be started on potassium citrate, while someone producing uric acid stones might receive allopurinol combined with citrate therapy.
But the landscape of kidney stone prevention is shifting. A landmark 2023 trial published in the New England Journal of Medicine challenged decades of confidence in hydrochlorothiazide, the most commonly prescribed thiazide diuretic for stone prevention. Meanwhile, kidney stone prevalence has surged — affecting roughly 1 in 11 Americans according to recent NHANES data, up from about 1 in 26 in the late 1970s. This article walks through the medications urologists prescribe, the evidence behind each one, which drugs are facing scrutiny, and what emerging research may change the prevention playbook in the coming years.
Table of Contents
- What Medications Do Urologists Prescribe for Kidney Stone Prevention, and How Do They Work?
- Why the Most Popular Thiazide May Not Work as Well as Doctors Thought
- How 24-Hour Urine Testing Guides Which Medication You Get
- Potassium Citrate vs. Thiazides — Comparing the Two Most Common Stone Prevention Drugs
- Side Effects and Risks That Stone Prevention Patients Should Know About
- Who Is Most at Risk and Why Stone Prevention Matters More for Some Patients
- Emerging Research and What the Future of Kidney Stone Prevention Looks Like
- Conclusion
- Frequently Asked Questions
What Medications Do Urologists Prescribe for Kidney Stone Prevention, and How Do They Work?
The three pillars of pharmacological kidney stone prevention target different parts of urine chemistry. Thiazide diuretics — including hydrochlorothiazide, chlorthalidone, and indapamide — work by reducing the amount of calcium the kidneys excrete into the urine. Less calcium in urine means fewer opportunities for calcium oxalate or calcium phosphate crystals to form. The American Urological Association recommends specific regimens: hydrochlorothiazide at 25 mg twice daily or 50 mg once daily, chlorthalidone at 25 mg once daily, or indapamide at 2.5 mg once daily. For over 50 years, thiazides have been considered the cornerstone of calcium stone prevention. Potassium citrate takes a different approach. Citrate in urine acts as a natural inhibitor of calcium stone crystallization — it binds to calcium before calcium can bind to oxalate, essentially blocking the first step of stone formation.
The AUA recommends potassium citrate for patients with recurrent calcium stones who show low urinary citrate levels on testing. It also serves double duty for uric acid stone formers because it alkalinizes urine, and uric acid stones dissolve in less acidic conditions. According to CARI guidelines updated in January 2026, tablets are preferred over liquid formulations because patients tolerate them better long-term. Allopurinol rounds out the core options. It reduces the body’s production of uric acid and is prescribed for patients who form uric acid stones or who have hyperuricosuria — excess uric acid spilling into the urine. This medication is particularly relevant for patients with gout or those whose diets are heavy in animal protein, which drives uric acid production. In practice, urologists often combine allopurinol with potassium citrate for uric acid stone formers, attacking the problem from two angles: reducing uric acid production while simultaneously making the urine environment hostile to uric acid crystal formation.
Why the Most Popular Thiazide May Not Work as Well as Doctors Thought
For decades, urologists prescribed hydrochlorothiazide with confidence built on older, smaller studies. That confidence took a serious hit in March 2023, when the NOSTONE trial — a rigorous, double-blind, randomized controlled trial of 416 patients — was published in the New England Journal of Medicine. The results were striking: hydrochlorothiazide at doses of 12.5 mg, 25 mg, and 50 mg showed no statistically significant reduction in kidney stone recurrence compared to placebo over a median follow-up of 2.9 years. The recurrence rate in the placebo group was 59 percent. At the highest tested dose of 50 mg, the rate was 49 percent — a difference that did not reach statistical significance. What makes this finding especially important is that hydrochlorothiazide is a short-acting thiazide, and it was the specific drug tested.
Chlorthalidone and indapamide, which are longer-acting and more potent per milligram, were not included in the NOSTONE trial. Many nephrologists and urologists now suspect that these longer-acting agents may still be effective where hydrochlorothiazide fell short. However, until a comparable randomized trial is conducted on chlorthalidone or indapamide, this remains an educated guess rather than proven fact. The trial also underscored the real costs of thiazide therapy even when the benefits are uncertain. Patients on hydrochlorothiazide experienced higher rates of hypokalemia, gout flares, new-onset diabetes, and skin allergies compared to those taking placebo. For a patient weighing whether to take a daily medication for years, these side effects matter — especially if the drug may not actually reduce their risk of forming another stone. This has prompted many urologists to reevaluate whether thiazides should remain automatic first-line therapy for every calcium stone former, or whether potassium citrate or dietary changes should take priority.
How 24-Hour Urine Testing Guides Which Medication You Get
The AUA guidelines are clear on one point: all patients with recurrent kidney stones should undergo 24-hour urine testing before medication is prescribed. This test requires collecting every drop of urine over a full day, which a laboratory then analyzes for calcium, oxalate, citrate, uric acid, sodium, and pH levels. The results function as a metabolic fingerprint that tells the urologist exactly which chemical imbalance is driving stone formation. Prescribing medication without this test is like prescribing glasses without checking someone’s vision. Consider a practical example. A 55-year-old man who has passed three calcium oxalate stones in five years gets a 24-hour urine collection done. The results show normal calcium levels but critically low citrate.
His urologist would prescribe potassium citrate rather than a thiazide, because his stone-forming problem is not excess calcium but insufficient citrate to block crystallization. A different patient — say a 45-year-old woman with high urinary calcium and normal citrate — might receive chlorthalidone instead. A third patient with uric acid stones and a urine pH of 5.2 would be started on potassium citrate to raise that pH, possibly with allopurinol if uric acid levels are also elevated. Blood monitoring also plays a role once treatment begins. Patients on thiazide therapy need periodic blood tests to check for hypokalemia — dangerously low potassium — and glucose intolerance, both known side effects. When potassium drops too low, urologists may add amiloride or spironolactone to the regimen. These potassium-sparing diuretics counteract the potassium loss from thiazides, avoiding the need for separate potassium supplements that many patients find hard to tolerate.
Potassium Citrate vs. Thiazides — Comparing the Two Most Common Stone Prevention Drugs
For calcium stone formers, the practical choice often comes down to potassium citrate or a thiazide diuretic, and each has distinct tradeoffs. Potassium citrate’s main advantage is its dual mechanism: it inhibits calcium stone formation and can dissolve uric acid stones. It does not carry the metabolic side effects that thiazides do — no increased diabetes risk, no gout flares, no potassium depletion. Its primary downsides are gastrointestinal. The tablets are large, and some patients experience nausea, bloating, or diarrhea. The CARI guidelines’ recommendation of tablets over liquid solutions reflects the reality that the liquid form tastes unpleasant enough to tank adherence.
Thiazides, on the other hand, are small pills taken once or twice daily with minimal GI complaints. They are inexpensive and widely available. But after the NOSTONE trial, the evidence specifically supporting hydrochlorothiazide — the most commonly prescribed thiazide for stones — has weakened considerably. Chlorthalidone and indapamide remain reasonable options based on older evidence and pharmacological logic, but a patient hearing that the biggest modern trial failed to show benefit for the most popular thiazide may reasonably ask whether the risk of side effects is worth it. In practice, many urologists are now leading with potassium citrate for patients whose 24-hour urine shows low citrate, reserving thiazides for those with documented hypercalciuria — genuinely elevated urinary calcium. For patients with both low citrate and high calcium, combination therapy remains common. The important point is that no single medication works for all stone types, and the best outcomes depend on matching the drug to the specific metabolic abnormality identified on testing.
Side Effects and Risks That Stone Prevention Patients Should Know About
The medications used for kidney stone prevention are generally safe, but long-term use introduces risks that deserve honest discussion. Thiazide diuretics can cause hypokalemia, which at its mildest produces muscle cramps and fatigue but at its worst can trigger dangerous heart rhythm disturbances. The NOSTONE trial documented that side effects including hypokalemia, gout, new-onset diabetes, and skin allergies were all more common in the hydrochlorothiazide groups than in the placebo group. For a medication class whose benefit is now under question for short-acting formulations, these risks carry more weight than they used to. Potassium citrate is generally better tolerated, but it is not without limitations. Patients with chronic kidney disease must use it cautiously, because impaired kidneys cannot efficiently clear excess potassium, and potassium citrate could push levels dangerously high.
Allopurinol, used for uric acid stones, can rarely cause severe hypersensitivity reactions including Stevens-Johnson syndrome — a serious skin condition. Patients of certain genetic backgrounds, particularly those of Southeast Asian or African American descent, are at higher risk and may be screened for the HLA-B*5801 allele before starting the drug. A less obvious risk is the false sense of security that medication can create. Some patients assume that taking a pill means they can stop worrying about fluid intake, sodium consumption, and diet. But the AUA guidelines are explicit: dietary modifications — drinking enough fluid to produce over 2.5 liters of urine daily, reducing sodium intake, and moderating animal protein consumption — remain first-line prevention before any medication is considered. Drugs are meant to supplement lifestyle changes, not replace them.
Who Is Most at Risk and Why Stone Prevention Matters More for Some Patients
Kidney stone prevalence now stands at roughly 10 percent of the American population, based on NHANES data from 2017 to 2020 — a dramatic rise from 3.8 percent in the late 1970s. Men are still affected more often than women (10.6 percent versus 7.1 percent), but that gap is narrowing as rates among women climb. Prevalence peaks sharply in older adults, reaching 23.9 percent in those aged 70 and older.
For older patients already managing conditions like osteoporosis, diabetes, or chronic kidney disease, recurrent stones are not just painful — they can accelerate kidney function decline and complicate existing treatment regimens. The roughly 2,054 stones per 100,000 adults seen annually means that emergency departments, urologists, and primary care physicians deal with this condition constantly. For patients who have already formed one stone, the recurrence risk without intervention is high, which is precisely why medication discussions matter. A 72-year-old woman with her third calcium oxalate stone and stage 3 chronic kidney disease, for instance, faces compounding health consequences with each episode — making effective prevention not just a quality-of-life issue but a matter of preserving remaining kidney function.
Emerging Research and What the Future of Kidney Stone Prevention Looks Like
Several lines of research may reshape stone prevention in the next few years. GLP-1 receptor agonists — the class of weight-loss drugs that includes semaglutide — are being explored for kidney stone prevention, since obesity is a well-established risk factor for stone formation. If these medications reduce stone risk as a secondary benefit of weight loss and metabolic improvement, they could offer a dual-purpose therapy for the growing population of patients who are both overweight and stone-prone.
Researchers at UF Health have identified existing FDA-approved drugs that may be repurposed to block kidney stone crystal development at the molecular level, potentially opening new prevention pathways without the lengthy timeline of novel drug development. Meanwhile, the AUA updated its surgical management guidelines in 2026 to incorporate AI-assisted and robotic-assisted procedures for stone treatment, signaling that both the medical and surgical sides of stone care are evolving rapidly. There is also growing interest in dual-purpose therapies that simultaneously prevent stones and slow chronic kidney disease progression — a particularly promising direction given the overlap between these two patient populations. For patients and clinicians alike, the next several years are likely to bring more targeted, evidence-based options than the field has had in decades.
Conclusion
Kidney stone prevention medication is not one-size-fits-all. The right prescription depends on stone composition, urine chemistry results from 24-hour testing, and the patient’s broader health picture. Potassium citrate, thiazide diuretics (with a growing preference for longer-acting agents like chlorthalidone over hydrochlorothiazide), and allopurinol each target different metabolic problems. The NOSTONE trial’s findings have injected healthy skepticism into what was previously routine prescribing, pushing the field toward more individualized, evidence-driven decisions.
For anyone dealing with recurrent kidney stones, the most important step is getting a proper metabolic workup — not just accepting a prescription based on the stone type alone. Dietary changes remain foundational, and medication should build on those habits rather than substitute for them. With emerging research into GLP-1 agonists, drug repurposing, and dual-purpose therapies, the toolkit for stone prevention is expanding. But the basics still hold: drink enough water, get tested, and work with a urologist who tailors the treatment plan to your specific chemistry.
Frequently Asked Questions
How long do you need to take kidney stone prevention medication?
Most urologists prescribe these medications indefinitely for patients with recurrent stones. Stone prevention is an ongoing process, not a short-term treatment. If the medication is stopped, the underlying metabolic abnormality that caused the stones typically returns, and with it the risk of new stone formation.
Can dietary changes alone prevent kidney stones without medication?
For some patients, yes. The AUA considers dietary modifications — increased fluid intake, reduced sodium, and moderate animal protein — as first-line prevention before medication. However, patients with severe metabolic abnormalities or frequent recurrences often need medication in addition to dietary changes to adequately lower their risk.
Is hydrochlorothiazide still prescribed for kidney stones after the NOSTONE trial?
Some urologists still prescribe it, but many are shifting toward chlorthalidone or indapamide, which are longer-acting thiazides that were not tested in the NOSTONE trial and may still be effective. The trial specifically showed that hydrochlorothiazide at multiple doses did not significantly reduce stone recurrence compared to placebo.
Does potassium citrate have fewer side effects than thiazide diuretics?
Generally, yes. Potassium citrate does not carry the risk of hypokalemia, gout, or new-onset diabetes associated with thiazides. Its main side effects are gastrointestinal — nausea, bloating, and diarrhea. However, it must be used cautiously in patients with chronic kidney disease due to the risk of elevated potassium levels.
What type of doctor should manage kidney stone prevention?
A urologist typically manages stone prevention, often in coordination with a nephrologist for patients with chronic kidney disease. Some academic medical centers have dedicated stone prevention clinics. The key is finding a provider who orders 24-hour urine testing and tailors medication to the results rather than prescribing empirically.
